ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- PrEP and Contraceptive Persistence Among Young Women Receiving Sexual and Reproductive Health Services Through Hair Salons in South Africa.Journal of acquired immune deficiency syndromes (1999) · 2026Trial
- Barriers and Facilitators to Equitable Implementation of Long-Acting Injectable PrEP for Racial, Gender and Sexual Minority Populations in NYC: The EquiPrEP Study.AIDS and behavior · 2026Article
- Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study.Lancet regional health. Americas · 2026Article
- Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.JAMA network open · 2026Article
- Brief Report: Long-Acting Injectable PrEP Can Substantially Reduce HIV Incidence in Los Angeles County: A Simulation Study.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Barriers to Same-Day Pre-exposure Prophylaxis (PrEP) Implementation in Federally Funded HIV Clinics Within High-Burden Areas of the U.S.: A Coincidence Analysis.AIDS and behavior · 2026Article
- Case study of PEPFAR funding cuts on HIV infections and deaths: reversing hard-won gains.AIDS (London, England) · 2025Article
- Why is roll-out of long-acting PrEP agents so slow?Current opinion in HIV and AIDS · 2025Review
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
In a low-barrier, long-acting preexposure prophylaxis (PrEP) program in a safety net setting, permitting same-day or next-day initiation, 85% of injections were on time, and 6-month retention was 83%, surpassing outcomes from most previously reported oral PrEP studies. With drop-in, wraparound services, similar retention among housing-insecure populations was seen. Long-acting PrEP expansion is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.